Companies › Pharmicell
1 active drug program in 1 registered trial: 1 Phase 3; Gastroenterology; next expected readout Dec 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cellgram-LC Autologous bone marrow-derived mesenchymal stem cells | – | Phase 3 | Alcoholic Cirrhosis | Dec 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04689152 | Cellgram-LC | Phase 3 | Alcoholic Cirrhosis | Gastroenterology | Dec 2029 |
No annotated target.
–
Akero Therapeutics Camurus VectivBio LyGenesis Mikrobiomik Healthcare Company
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.